

Appl. No. 10/733,042

Reply to Office action of April 20, 2007

This listing of claims will replace all prior versions and listings of claims in the application:

Listing of Claims:

1. (currently amended) ~~An isolated nucleic acid molecule~~ The nucleic acid molecule of claim 6 comprising an avian matrix attachment region and an avian ovalbumin transcriptional regulatory region.
2. (currently amended) The nucleic acid molecule ~~according to~~ of Claim 6 ~~1~~, further comprising a ~~second~~ matrix attachment region.
3. (currently amended) The nucleic acid molecule ~~according to~~ of Claim 6 ~~1~~, comprising an avian 5' matrix attachment region and an avian 3' matrix attachment region.
4. (currently amended) The nucleic acid molecule ~~according to~~ of Claim 6 ~~1~~, wherein the nucleic acid molecule is isolated from a chicken cell.
5. (canceled)
6. (currently amended) ~~The nucleic acid molecule according to Claim 1,~~ A nucleic acid molecule comprising a nucleotide sequence having at least about 95% identity to the nucleotide sequence ~~according to~~ of SEQ ID NO: 1, or the complement thereof.
7. (currently amended) The nucleic acid molecule ~~according to~~ of Claim 6 ~~1~~, comprising a nucleotide sequence having at least about 99% identity to the nucleotide sequence ~~according to~~ of SEQ ID NO: 1, or the complement thereof.
8. (currently amended) The nucleic acid molecule ~~according to~~ of Claim 6 ~~1~~, comprising the nucleotide sequence ~~according to~~ of SEQ ID NO: 1, or the complement thereof.

Appl. No. 10/733,042

Reply to Office action of April 20, 2007

9. (currently amended) The nucleic acid molecule ~~according to~~ of Claim 6 ~~4~~, wherein the nucleic acid molecule consists of the nucleotide sequence ~~according to~~ of SEQ ID NO: 1, or the complement thereof.
10. (canceled)
11. (canceled)
12. (canceled)
13. (canceled)
14. (canceled)
15. (canceled)
16. (canceled)
17. (canceled)
18. (canceled)
19. (canceled)
20. (canceled)
21. (canceled)
22. (canceled)

Appl. No. 10/733,042

Reply to Office action of April 20, 2007

23. (currently amended) A vector ~~having inserted therein a nucleic acid molecule according to Claim 1~~ comprising a nucleotide sequence having at least about 95% identity to the nucleotide sequence of SEQ ID NO: 1.
24. (currently amended) The vector ~~according to~~ of Claim 23 selected from the group consisting of an artificial chromosome, a plasmid vector and a viral vector.
25. (currently amended) A liposome composition comprising a ~~the~~ nucleic acid molecule ~~according to~~ of Claim 1.
26. (currently amended) ~~The nucleic acid molecule according to Claim 1,~~ A nucleic acid molecule comprising a nucleotide sequence having at least about 95% identity to the nucleotide sequence of SEQ ID NO: 1 wherein the nucleic acid molecule is a recombinant nucleic acid molecule.
27. (canceled)
28. (canceled)
29. (currently amended) The recombinant nucleic acid molecule ~~according to~~ of Claim 26; further comprising a first polypeptide-encoding region ~~heterologous nucleic acid sequence~~ operably linked to the ovalbumin transcriptional regulatory region.
30. (currently amended) The recombinant nucleic acid molecule ~~according to~~ of Claim 26; further comprising an endogenous nucleic acid sequence operably linked to the ovalbumin transcriptional regulatory region.
31. (currently amended) The recombinant nucleic acid molecule ~~according to~~ of Claim 26; wherein the ovalbumin transcriptional regulatory region is capable of tissue-specific transcription by an avian oviduct cell.

Appl. No. 10/733,042
Reply to Office action of April 20, 2007

32. (currently amended) The recombinant nucleic acid molecule ~~according to~~ of Claim 26, further comprising an Internal Ribosome Entry Site.
33. (currently amended) The recombinant nucleic acid molecule ~~according to~~ of Claim ~~29~~ 32, further comprising a ~~second heterologous nucleic acid sequence~~ polypeptide encoding region operably linked to the Internal Ribosome Entry Site.
34. (canceled)
35. (currently amended) The vector ~~according to~~ of Claim 34 selected from the group consisting of a bacterial artificial chromosome, a yeast artificial chromosome, a plasmid vector and a viral vector.
36. (currently amended) The recombinant nucleic acid molecule ~~according to~~ of Claim 26, further comprising a polyadenylation signal sequence.
37. (currently amended) The recombinant nucleic acid molecule ~~according to~~ of Claim 29, wherein the ~~heterologous~~ nucleic acid sequence encoding the ~~encodes a~~ polypeptide has having a codon complement optimized for protein expression in an avian.
38. (currently amended) The recombinant nucleic acid molecule ~~according to~~ of Claim 26 further comprising an origin of replication selected from the group consisting of a bacterial origin of replication and a viral origin of replication.
39. (currently amended) The recombinant nucleic acid molecule ~~according to~~ of Claim 26 which A nucleic acid molecule comprising a nucleotide sequence having at least about 95% identity to the nucleotide sequence ~~according to~~ of SEQ ID NO: 1 comprises is a bacterial artificial chromosome.

Appl. No. 10/733,042
Reply to Office action of April 20, 2007

40. (canceled)
41. (canceled)
- 42-70 (canceled)
71. (new) The nucleic acid molecule of Claim 6 comprising a heterologous coding sequence encoding a pharmaceutical protein.
72. (new) The vector of Claim 23 comprising a heterologous coding sequence encoding a pharmaceutical protein.
73. (new) The nucleic acid molecule of Claim 26 comprising a heterologous coding sequence encoding a pharmaceutical protein.
74. (new) The vector of Claim 23 comprising a nucleotide sequence having at least about 99% identity to the nucleotide sequence of SEQ ID NO: 1.
75. (new) The vector of Claim 23 comprising the nucleotide sequence of SEQ ID NO: 1.
76. (new) A MAR element between nucleotide 41701 and nucleotide 41900 of SEQ ID NO: 1.
77. (new) A MAR element between nucleotide 96401 and nucleotide 96800 of SEQ ID NO: 1.